Vimarsana
Biggest News Aggregation in the World

Page 8 - Erick Rowinsky News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Erick Rowinsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Erick Rowinsky Today - Breaking & Trending Today

OVERSEA CHINESE BANKING Corp Ltd Buys 750 Shares of Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

OVERSEA CHINESE BANKING Corp Ltd Buys 750 Shares of Biogen Inc. (NASDAQ:BIIB)

OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 6.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 11,770 shares of the biotechnology company’s stock after acquiring an additional 750 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Biogen were worth […]

AIA Group Ltd Decreases Position in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

AIA Group Ltd Decreases Position in Biogen Inc. (NASDAQ:BIIB)

AIA Group Ltd cut its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 8.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,563 shares of the biotechnology company’s stock after selling 141 shares during the period. AIA Group Ltd’s holdings […]

Wedbush Equities Analysts Decrease Earnings Estimates for Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Wedbush Equities Analysts Decrease Earnings Estimates for Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB – Free Report) – Investment analysts at Wedbush dropped their Q1 2024 earnings per share estimates for Biogen in a report issued on Wednesday, April 17th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings of $3.25 per share for the quarter, down from their prior estimate of […]

Biogen (NASDAQ:BIIB) PT Lowered to $214.00 - Vimarsana News

Biogen (NASDAQ:BIIB) PT Lowered to $214.00

Biogen (NASDAQ:BIIB – Get Free Report) had its price objective cut by research analysts at UBS Group from $250.00 to $214.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s price objective indicates a potential upside of 11.37% from the stock’s […]

UBS Group Lowers Biogen (NASDAQ:BIIB) Price Target to $214.00 - Vimarsana News

UBS Group Lowers Biogen (NASDAQ:BIIB) Price Target to $214.00

Biogen (NASDAQ:BIIB – Get Free Report) had its price objective reduced by analysts at UBS Group from $250.00 to $214.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s price objective points to a potential upside of 11.37% from the […]